

Information For the Use of
Empagliflozin (12.5mg) + Metformin (500mg) Tablet

Emplozin M 12.5/500 Tablet

Brand Name: Emplozin M 12.5/500 Tablet

Dosage Form: Tablet

Composition:

Each film-coated tablet contains:

- Empagliflozin IP 12.5 mg
- Metformin Hydrochloride IP 500 mg

Description:

Emplozin M 12.5/500 Tablet is a fixed-dose combination of Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin, a biguanide antihyperglycemic agent. It is indicated for the management of type 2 diabetes mellitus when glycemic control is not adequately achieved with monotherapy. It helps in improving glycemic control through complementary mechanisms, reducing both fasting and post-prandial blood glucose levels.

Indications:

Indicated for the treatment of:

- Type 2 diabetes mellitus
- Patients inadequately controlled on metformin or empagliflozin alone
- As an adjunct to diet and exercise for glycemic control

It helps in improving blood glucose regulation and reducing long-term diabetic complications.

Dosage & Administration:

Dosage should be as directed by the physician.

The tablet should be taken with meals to reduce gastrointestinal side effects.

Regular monitoring of blood glucose and renal function is recommended during therapy.

Pharmacological Action:

- Empagliflozin inhibits SGLT2 in the renal proximal tubules, increasing urinary glucose excretion and lowering blood glucose levels independently of insulin.
- Metformin reduces hepatic glucose production, increases insulin sensitivity, and decreases intestinal glucose absorption.

Together, these mechanisms provide synergistic glycemic control.

Side Effects:

Common side effects include urinary tract infection, genital infections, nausea, diarrhea, abdominal discomfort, and increased urination.

Rarely, dehydration, ketoacidosis (with SGLT2 inhibitors), or lactic acidosis (with metformin) may occur.

Precautions & Warnings:

- Monitor renal function before and during therapy
- Risk of volume depletion and hypotension with SGLT2 inhibitors

- **Use with caution in elderly patients and those with renal impairment**
 - **Temporarily discontinue before major surgery or severe illness**
 - **Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis**
-

Drug Interactions:

May interact with diuretics, insulin, and other antidiabetic agents, increasing risk of hypoglycemia or dehydration.

Caution with drugs affecting renal function.

Storage:

Store below 25°C in a cool, dry place.

Protect from moisture and light.

Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I, Panchkula-134113

Corporate Office :

Plot no. 307, Industrial Area Phase-2,

Panchkula, Haryana -134113

TM: Trademark Applied for